A simple free-catch urine analysis system offering the most rapid and reliable TCC/UC detection.
By offering a robust, rapid and highly sensitive diagnostic solution, veterinarians can focus on earliest detection of canine TCC/UC. This provides clinicians with the opportunity to offer their clients the most appropriate clinical management of their dogs with more time to combat the cancer sooner in the course of the disease.
This year, 80,000 dogs will be diagnosed with canine transitional cell carcinoma (TCC), also now known as urothelial carcinoma (UC). Using existing techniques most diagnoses are made when the cancer is at an advanced stage and has invaded the muscle wall. In 20% of cases the cancer has already spread (metastasized) to other parts of the body. These features all indicate that current diagnostic methods have very limited ability for early detection of the disease, which may in turn reduce treatment options and lead to a less favorable outcome.
Our research at Sentinel Biomedical has shown that a single mutation in a gene called BRAF is present in 85% of confirmed cases of canine TCC/UC. With highly sensitive molecular technology, we have developed a genetic test that can detect the presence of this mutation in cells naturally shed into the urine of an affected dog. The mutation is not found in the urine of healthy dogs, or from dogs that have nonmalignant bladder polyps, inflammation or cystitis. It is therefore a highly specific indicator of the presence of a TCC/UC.
To learn more about the science behind the development of this assay click on this link to read the published study (link will open a new tab/window)
CADETSM BRAF Mutation Detection Assay
Sentinel Biomedical now offers a unique DNA-based strategy for early detection of canine TCC/UC. The CADETSM BRAF Mutation Detection Assay can detect as few as 10 mutation-bearing cells in a urine sample, several months before any clinical signs associated with the cancer become evident. This enables owners and veterinarians to initiate appropriate treatment very early in the course of the disease, potentially before the mass has become invasive. Additionally, the test allows a sensitive means to monitor affected dogs during the course of their treatment, for therapeutic response and relapse.
Unlike previous, less discriminatory tests for canine TCC/UC, the CADETSM BRAF Mutation Detection Assay is not affected by the presence of blood or bacteria in the urine. Importantly, for cases that have undergone biopsy of a visible mass, there is 100% concordance between the presence of a BRAF mutation in free-catch urine and subsequent pathology-based confirmation of a TCC/UC.
Conversely, the BRAF mutation has not been detected among hundreds of urine samples from dogs that had been diagnosed with non-malignant bladder masses or other forms of cancer. These findings demonstrate that detection of the BRAF mutation in canine urine is a highly specific indicator of the presence of a TCC/UC.